Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IrAE”

41 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 41 results

Not applicableStudy completedNCT06247865
What this trial is testing

BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE

Who this might be right for
Neoplasms
Portsmouth Hospitals NHS Trust 120
Not applicableLooking for participantsNCT06613165
What this trial is testing

Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer

Who this might be right for
Immune-related Adverse EventNeoadjuvant TherapydMMR Colorectal Cancer
Xijing Hospital 100
Not applicableStudy completedNCT04513678
What this trial is testing

Development of ImmunOncoTool

Who this might be right for
CancerCancer, Treatment-Related
Northwestern University 64
Not applicableLooking for participantsNCT06461780
What this trial is testing

Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy

Who this might be right for
CancerImmunotherapyIrAE+4 more
Taipei Veterans General Hospital, Taiwan 200
Not applicableUnknownNCT06243250
What this trial is testing

Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events

Who this might be right for
Immune-related Adverse Event
Chang Gung Memorial Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06037811
What this trial is testing

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Who this might be right for
Inflammatory ArthritisImmune-related Adverse Event
Tom Appleton 30
Very early researchNot Yet RecruitingNCT06908018
What this trial is testing

Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)

Who this might be right for
Safety IssuesDengueViremia+1 more
Mahidol University 12
Not applicableLooking for participantsNCT03989323
What this trial is testing

A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

Who this might be right for
Cancer
Hospices Civils de Lyon 2,000
Not applicableLooking for participantsNCT05813418
What this trial is testing

Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Who this might be right for
ImmunotherapyImmune Checkpoint InhibitorsImmune-related Adverse Event+1 more
Centre Hospitalier Universitaire, Amiens 150
Not applicableNot Yet RecruitingNCT07119190
What this trial is testing

A Perioperative Comprehensive Diagnosis and Treatment System for Lung Cancer in the Era of Neoadjuvant Immunotherapy

Who this might be right for
Non-Small Cell Lung Cancer
Peking University People's Hospital 350
Not applicableStudy completedNCT04960059
What this trial is testing

NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts

Who this might be right for
CancerMetastatic MelanomaRenal Cell Carcinoma+1 more
The Christie NHS Foundation Trust 24
Testing effectiveness (Phase 2)Looking for participantsNCT06860542
What this trial is testing

Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis

Who this might be right for
PneumonitisImmune-related Adverse Event
AHS Cancer Control Alberta 94
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07381634
What this trial is testing

The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities

Who this might be right for
Hepatocellular Carcinoma (HCC)IrAE
First Affiliated Hospital of Wenzhou Medical University 134
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07303881
What this trial is testing

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Who this might be right for
IrAEHematologic DisorderLung Cancer (Locally Advanced or Metastatic)
The First Affiliated Hospital of Guangzhou Medical University 16
Not applicableEnded earlyNCT05699915
What this trial is testing

Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

Who this might be right for
CancerImmune-related Adverse EventCardiac Abnormalities, Variable+4 more
Algemeen Ziekenhuis Maria Middelares 105
Not applicableLooking for participantsNCT05832606
What this trial is testing

Food Intervention to Reduce Immunotherapy ToXicity

Who this might be right for
Immune-related Adverse EventDietary Habits
Universitair Ziekenhuis Brussel 60
Not applicableStudy completedNCT03447483
What this trial is testing

Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).

Who this might be right for
Solid Tumor
Institut Claudius Regaud 150
Not applicableStudy completedNCT06440811
What this trial is testing

Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Immune-related Adverse EventChemotherapeutic ToxicityGastric or Gastroesophageal Junction Adenocarcinoma
Xijing Hospital 120
Not applicableLooking for participantsNCT06702566
What this trial is testing

The Effect of Serum Ferritin in irAE

Who this might be right for
Immune-related Adverse EventMalignant Solid TumorsAcute Leukemia+1 more
Tianjin Medical University Cancer Institute and Hospital 1,500
Testing effectiveness (Phase 2)WithdrawnNCT04060407
What this trial is testing

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Who this might be right for
Metastatic Melanoma
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Load More Results